Tiziana Life Sciences: Robust Pipeline with Multiple Near-Term Catalysts

Apr. 29, 2021
Tiziana Life Sciences (NASDAQ: TLSA) has developed proprietary oral, nasal, and inhaled formulation technologies that could transform immunotherapies with Monoclonal Antibodies currently administered intravenously for multiple indications. Through multiple Phase 2 trials underway and/or planned, the Company is positioned for a steady stream of milestone achievements over the next several quarters, including launch of a Phase 2 COVID-19 trial. Led by a world-class leadership team and scientific advisory board with a collective 76 years of experience in medical technology and more than 100 medical product launches, Tiziana is ideally positioned to execute on its robust corporate strategy.

 Read More

"I work with many of the companies that would be RedChip companies. And we certainly ascribe to the same view that the RedChip Companies do, which is Discovering Tomorrow's Blue Chips Today."

  • Bob McCooey, Senior Vice President, NASDAQ Stock Market